Teva Gets FDA Approval For New Nasal Allergy Treatment

Teva Pharmaceutical Industries announced today that the U.S. Food and Drug Administration (FDA) has approved QNASL Nasal Aerosol, a new ‘dry’ nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years and older. The product is expected to be available by prescription on April 2012 and offers a built-in dose counter. The approval follows a comprehensive clinical development program that assessed the product’s safety and efficacy.